Filters

See more specimen types...
See more states

Other countries

See more countries

Results: 1 to 20 of 159

Tests names and labsConditionsGenes and analytesMethods

CentoCancer panel

Centogene AG - the Rare Disease Company
Germany
5231
  • C Sequence analysis of the entire coding region

CentoBreast (hereditary breast cancer) panel

Centogene AG - the Rare Disease Company
Germany
1013
  • C Sequence analysis of the entire coding region

Breast cancer

Centogene AG - the Rare Disease Company
Germany
41
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Familial BRCA1 and BRCA2 mutation analysis

Genetic Services Laboratory University of Chicago
United States
22
  • T Targeted variant analysis

Hereditary Cancer Panel Comprehensive

Molecular Genetics Laboratory London Health Sciences Center
Canada
3625
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

BRCA ashkenazi

Laboratorio de Patologia Integral y Diagnostico Oportuno
Mexico
22
  • X Mutation scanning of select exons

Breast cancer susceptibility to

Centogene AG - the Rare Disease Company
Germany
11
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Breast ovarian cancer panel

Centogene AG - the Rare Disease Company
Germany
1914
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

BRCA1-Hereditary Cancer of the Breast

Molecular Genetics Laboratory London Health Sciences Center
Canada
21
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

BRCA Panel

Castle Medical Molecular Diagnostics Castle Medical, LLC
United States
22
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Hereditary Cancer Panel - High Penetrance 16

Molecular Genetics Laboratory London Health Sciences Center
Canada
2816
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Hereditary Breast and Ovarian Cancer BRCA1&2

GeneKor MSA
Greece
52
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

High Risk Breast Cancer: Sequencing and Deletion/Duplication Panel

Emory Genetics Laboratory Emory University
United States
66
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Hereditary Breast and Ovarian Cancer BRCA1/2 Sequencing and Deletion/Duplication Panel

PreventionGenetics
United States
42
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Tier 2: Familial Myelodysplastic Syndrome/Acute Leukemia (MDS/AL) Panel

Genetic Services Laboratory University of Chicago
United States
1114
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

TruGenome Predisposition Screen (Whole Genome Sequencing)

Illumina Clinical Services Laboratory Illumina
United States
15391578
  • C Sequence analysis of the entire coding region

BRCA2. MLPA testing

Instituto de Medicina Genomica
Spain
41
  • D Deletion/duplication analysis

BRCA1, BRCA2. NextGeneDx.Complete sequencing by NGS

Instituto de Medicina Genomica
Spain
42
  • C Sequence analysis of the entire coding region

BRCA1. MLPA testing

Instituto de Medicina Genomica
Spain
41
  • D Deletion/duplication analysis

BRCA1. Complete sequencing

Instituto de Medicina Genomica
Spain
41
  • C Sequence analysis of the entire coding region

Results: 1 to 20 of 159

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.